Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

AstraZeneca : BEST OF THE BROKERS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/15/2017 | 07:21am CEST

Things are looking up for pharma giant Astrazeneca, Liberum analysts have said. Recent drug trials have driven the firm's shares back up to where they were before high-profile problems connected with the failure of lung cancer drug Imfinzi. Analysts downgrade the firm to a "hold" but hike Astra's target price to 5,000P.

Analysts from Cantor Fitzgerald praised home furnishings firm Dunelm for investing in growth over the last year. Such investment is paying dividends already, they say, with sales set to grow to over £2bn in the medium-term. Cantor brokers stick to their "buy" rating and target price of 780p.

(c) 2017 City A.M., source Newspaper

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA -0.36% 5589 Delayed Quote.9.14%
DUNELM GROUP PLC 2.38% 517 Delayed Quote.-25.34%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
07/20ASTRAZENECA : EU drug regulators step up work to prepare for 'no deal' Brexit
RE
07/18ASTRAZENECA : Increases Drug Stockpile in Preparation for Hard Brexit
DJ
07/18ASTRAZENECA : to stockpile drugs as Brexit 'safety net'
RE
07/18ASTRAZENECA : 10.1% Potential Upside Indicated by Deutsche Bank
AQ
07/18Fetal gene therapy could treat neurodegenerative disease
AQ
07/16ASTRAZENECA : Swedish Business Appoints New CEO
DJ
07/16ADVAXIS : rises after FDA lifts clinical hold
AQ
07/12ASTRAZENECA : FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic ..
AQ
07/12Novartis Becomes Latest Player to Exit Antibiotic, Antiviral Research
DJ
07/06HITTING CANCER EARLY : AstraZeneca's bid to outmaneuver rivals
RE
More news
News from SeekingAlpha
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/18FDA committed to easing approval path for biosimilars 
07/18AstraZeneca to stockpile drugs ahead of Brexit 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/15BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Cytodyn's Acquisition, Novartis Exits Ant.. 
Financials ($)
Sales 2018 22 201 M
EBIT 2018 5 245 M
Net income 2018 1 969 M
Debt 2018 14 506 M
Yield 2018 3,71%
P/E ratio 2018 39,35
P/E ratio 2019 31,73
EV / Sales 2018 4,82x
EV / Sales 2019 4,55x
Capitalization 92 447 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 74,8 $
Spread / Average Target 1,9%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA9.14%92 447
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-1.75%206 705
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171